Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of raltegravir dose strategies versus efavirenz with tenofovir and lamivudine in treatment-naive HIV-1 patients receiving rifampin for active tuberculosis
2008-004970-41Phase 2Active
- Sponsor
- ANRS
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of raltegravir and efavirenz in Human immunodeficiency virus infection type 1 and Tuberculosis (TB) (3 arms), sponsored by ANRS. Primary endpoint: Virologic success at week 24. Started Nov 2008; status: active.
02
Drugs
raltegravirefavirenz
03
Conditions
Human immunodeficiency virus infection type 1Tuberculosis (TB)
Beyond the preview
Go deeper on 2008-004970-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004970-41.